LifeMD’s (LFMD) “Buy” Rating Reiterated at B. Riley

B. Riley reissued their buy rating on shares of LifeMD (NASDAQ:LFMD) in a research note released on Tuesday, Benzinga reports. B. Riley currently has a $12.00 price target on the stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a buy rating and issued a $12.00 price target on shares of LifeMD in a report on Friday, May 10th. Cantor Fitzgerald boosted their target price on shares of LifeMD from $13.00 to $15.00 and gave the company an overweight rating in a research note on Thursday, May 9th. Finally, BTIG Research raised their price target on shares of LifeMD from $13.00 to $14.00 and gave the stock a buy rating in a research note on Tuesday, April 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of Buy and an average price target of $12.60.

LifeMD Trading Down 2.2 %

NASDAQ:LFMD opened at $7.62 on Tuesday. LifeMD has a 52 week low of $1.93 and a 52 week high of $12.88. The firm has a 50-day moving average price of $10.23 and a two-hundred day moving average price of $8.21. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.94 and a current ratio of 0.99. The firm has a market cap of $322.25 million, a price-to-earnings ratio of -10.30 and a beta of 1.38.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $44.86 million for the quarter, compared to analysts’ expectations of $40.65 million. On average, equities analysts expect that LifeMD will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LifeMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LFMD. Barclays PLC bought a new stake in shares of LifeMD in the third quarter valued at approximately $142,000. Citigroup Inc. bought a new stake in LifeMD during the 3rd quarter valued at $266,000. Jump Financial LLC raised its holdings in LifeMD by 50.2% during the 4th quarter. Jump Financial LLC now owns 111,738 shares of the company’s stock valued at $926,000 after acquiring an additional 37,339 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in shares of LifeMD in the fourth quarter worth $173,000. Finally, Thompson Davis & CO. Inc. bought a new position in shares of LifeMD in the fourth quarter worth $117,000. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.